Business
Trevi Therapeutics Announces Publication of Positive Data from the CANAL Trial in IPF Chronic Cough in NEJM Evidence
Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough The mean change in 24-hour
About this update from Trevi Therapeutics, Inc.
[{"type":"text","content":"Nalbuphine ER resulted in a rapid and marked reduction in recorded daytime cough among patients suffering from IPF-related cough\nThe mean change in 24-hour objective cough frequency was similar in patients with concomitant anti-fibrotic therapy and without concomitant anti-fibrotic therapy\nNEW HAVEN, Conn., May 22, 2023 /PRNewswire/ -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company developing the investigational therapy Haduvio™ (oral nalbuphine ER) for difficult to treat patients with chronic cough in idiopathic pulmonary fibrosis (IPF), other chronic cough indications, and prurigo nodularis, today announced the positive results from the Phase 2 CANAL trial in adults with IPF chronic cough has been published in NEJM Evidence.\n\n \n \n \n \n \n \n\n \nToby Maher, M.D., Ph.D., Professor of Clinical Medicine, Keck School of Medicine, University of Southern California, and the national corresponding investigator on the trial, said, \"The publication of these Phase 2 results in NEJM Evidence demonstrates the potential clinical benefit of targeting both the central and peripheral mechanisms of chronic cough with nalbuphine ER for adults with idiopathic pulmonary fibrosis. Every day in my clinical practice, I see the devastating impact of chronic cough on the lives of individuals with IPF. This challenging and debilitating symptom urgently requires effective treatments. We would like to thank all the investigators, study staff, and patients who participated in the CANAL trial.\"\nAccess publication here: https://evidence.nejm.org/doi/full/10.1056/EVIDoa2300083 \nThe safety results of the CANAL trial were generally consistent with the known safety profile of Haduvio from previous trials. There were two serious adverse events reported during the trial, neither of which was considered by the investigator to be treatment related. The most frequently reported treatment emergent adverse events associated with Haduvio in the CANAL trial were nausea, fatigue, dizziness, vomiting, constipation, and somnolence.\nAbout IPF\nThere are estimated to be 140,000 IPF patients in the US and more than 1 million patients ex-US, with up to 85% of these patients experiencing chronic cough. There are no approved therapies for the treatment of chronic cough in IPF, and the cough is often refractory to antitussive thera...